Literature DB >> 20605782

Factor VIII and platelets synergistically accelerate cleavage of von Willebrand factor by ADAMTS13 under fluid shear stress.

Christopher G Skipwith1, Wenjing Cao, X Long Zheng.   

Abstract

Previous studies have demonstrated that factor VIII (FVIII) or platelets alone increase cleavage of von Willebrand factor (VWF) by ADAMTS13 under mechanically induced shear stresses. We show in this study that the combination of FVIII and platelets at the physiological concentrations is more effective than either one alone. In the absence of FVIII, lyophilized platelets increase the formation of cleavage product by 2-3-fold. However, in the presence of physiological concentration of FVIII (1 nm), the formation of VWF cleavage product increases dramatically as a function of increasing platelets with the maximal rate enhancement of approximately 8-fold. Conversely, in the presence of a physiological concentration of lyophilized platelets (150 x 10(3)/microl), the half-maximal concentration of FVIII required to accelerate VWF proteolysis by ADAMTS13 reduces by approximately 10-fold (to approximately 0.3 nm) compared with that in the absence of platelets ( approximately 3.0 nm). Further studies using the FVIII derivative that lacks an acidic region (a3), an antiplatelet glycoprotein 1balpha IgG, and a purified recombinant VWF-A1 domain or glycoprotein 1balpha-stripped platelets demonstrate that the synergistic rate-enhancing effect of FVIII and platelets depends on their specific binding interactions with VWF. Our findings suggest that FVIII and platelets are cofactors that regulate proteolysis of multimeric VWF by ADAMTS13 under physiological conditions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20605782      PMCID: PMC2937885          DOI: 10.1074/jbc.M110.131227

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

1.  The proximal carboxyl-terminal domains of ADAMTS13 determine substrate specificity and are all required for cleavage of von Willebrand factor.

Authors:  Jihui Ai; Paula Smith; Shuwei Wang; Ping Zhang; X Long Zheng
Journal:  J Biol Chem       Date:  2005-06-23       Impact factor: 5.157

Review 2.  von Willebrand factor.

Authors:  J E Sadler
Journal:  J Biol Chem       Date:  1991-12-05       Impact factor: 5.157

3.  Shear-dependent changes in the three-dimensional structure of human von Willebrand factor.

Authors:  C A Siedlecki; B J Lestini; K K Kottke-Marchant; S J Eppell; D L Wilson; R E Marchant
Journal:  Blood       Date:  1996-10-15       Impact factor: 22.113

4.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.

Authors:  G G Levy; W C Nichols; E C Lian; T Foroud; J N McClintick; B M McGee; A Y Yang; D R Siemieniak; K R Stark; R Gruppo; R Sarode; S B Shurin; V Chandrasekaran; S P Stabler; H Sabio; E E Bouhassira; J D Upshaw; D Ginsburg; H M Tsai
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

5.  Acquired von Willebrand syndrome in aortic stenosis.

Authors:  André Vincentelli; Sophie Susen; Thierry Le Tourneau; Isabelle Six; Olivier Fabre; Francis Juthier; Anne Bauters; Christophe Decoene; Jenny Goudemand; Alain Prat; Brigitte Jude
Journal:  N Engl J Med       Date:  2003-07-24       Impact factor: 91.245

6.  Association of the factor VIII light chain with von Willebrand factor.

Authors:  P Lollar; D C Hill-Eubanks; C G Parker
Journal:  J Biol Chem       Date:  1988-07-25       Impact factor: 5.157

Review 7.  Shear stress and von Willebrand factor in health and disease.

Authors:  Han-Mou Tsai
Journal:  Semin Thromb Hemost       Date:  2003-10       Impact factor: 4.180

8.  Studies with a murine monoclonal antibody that abolishes ristocetin-induced binding of von Willebrand factor to platelets: additional evidence in support of GPIb as a platelet receptor for von Willebrand factor.

Authors:  B S Coller; E I Peerschke; L E Scudder; C A Sullivan
Journal:  Blood       Date:  1983-01       Impact factor: 22.113

9.  Platelet-VWF complexes are preferred substrates of ADAMTS13 under fluid shear stress.

Authors:  Kyuhwan Shim; Patricia J Anderson; Elodee A Tuley; Erin Wiswall; J Evan Sadler
Journal:  Blood       Date:  2007-09-27       Impact factor: 22.113

10.  Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity.

Authors:  Koichi Kokame; Masanori Matsumoto; Kenji Soejima; Hideo Yagi; Hiromichi Ishizashi; Masahisa Funato; Hiroshi Tamai; Mutsuko Konno; Kei Kamide; Yuhei Kawano; Toshiyuki Miyata; Yoshihiro Fujimura
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-14       Impact factor: 11.205

View more
  28 in total

1.  Shear-Induced Unfolding and Enzymatic Cleavage of Full-Length VWF Multimers.

Authors:  Svenja Lippok; Matthias Radtke; Tobias Obser; Lars Kleemeier; Reinhard Schneppenheim; Ulrich Budde; Roland R Netz; Joachim O Rädler
Journal:  Biophys J       Date:  2016-02-02       Impact factor: 4.033

Review 2.  Structure-function and regulation of ADAMTS-13 protease.

Authors:  X L Zheng
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

3.  Platelet transactivation by monocytes promotes thrombosis in heparin-induced thrombocytopenia.

Authors:  Valerie Tutwiler; Daria Madeeva; Hyun Sook Ahn; Izabella Andrianova; Vincent Hayes; X Long Zheng; Douglas B Cines; Steven E McKenzie; Mortimer Poncz; Lubica Rauova
Journal:  Blood       Date:  2015-10-30       Impact factor: 22.113

Review 4.  ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng
Journal:  Annu Rev Med       Date:  2015       Impact factor: 13.739

5.  Internal tension in a collapsed polymer under shear flow and the connection to enzymatic cleavage of von Willebrand factor.

Authors:  Matthias Radtke; Svenja Lippok; Joachim O Rädler; Roland R Netz
Journal:  Eur Phys J E Soft Matter       Date:  2016-03-22       Impact factor: 1.890

6.  Unconjugated bilirubin inhibits proteolytic cleavage of von Willebrand factor by ADAMTS13 protease.

Authors:  R-N Lu; S Yang; H M Wu; X L Zheng
Journal:  J Thromb Haemost       Date:  2015-04-23       Impact factor: 5.824

Review 7.  Pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  J Evan Sadler
Journal:  Blood       Date:  2017-08-02       Impact factor: 22.113

8.  Therapeutic efficacy of the platelet glycoprotein Ib antagonist anfibatide in murine models of thrombotic thrombocytopenic purpura.

Authors:  Liang Zheng; Yingying Mao; Mohammad S Abdelgawwad; Nicole K Kocher; Mandy Li; Xiangrong Dai; Benjamin Li; X Long Zheng
Journal:  Blood Adv       Date:  2016-11-29

Review 9.  Antigen and substrate withdrawal in the management of autoimmune thrombotic disorders.

Authors:  Douglas B Cines; Keith R McCrae; X Long Zheng; Bruce S Sachais; Eline T Luning Prak; Don L Siegel
Journal:  Blood       Date:  2012-09-10       Impact factor: 22.113

10.  Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial.

Authors:  Pier Mannuccio Mannucci; Christine Kempton; Carolyn Millar; Edward Romond; Amy Shapiro; Ingvild Birschmann; Margaret V Ragni; Joan Cox Gill; Thynn Thynn Yee; Robert Klamroth; Wing-Yen Wong; Miranda Chapman; Werner Engl; Peter L Turecek; Tobias M Suiter; Bruce M Ewenstein
Journal:  Blood       Date:  2013-06-18       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.